



مركز الكويت لمكافحة السرطان  
Kuwait Cancer Control Center

# LAPatinib (Tykerb®)



\* L A P - 0 0 0 0 0 - D L - C N - B R \*



Ministry of Health

**Name:**

**File #:**

**Ht (cm):**

**Nationality:**

**Civil ID:**

**Wt (Kg):**

**Gender/Age:**

**DOB:**

**BSA (m<sup>2</sup>):**

**Indication(s):** HER +ve metastatic breast cancer.

**Central line:**  Available  NA

**Allergies:**  NKA  Yes, specify; \_\_\_\_\_

**Standard Protocol:**

| DRUG   | DOSE                  | ADMINISTRATION  |
|--|-----------------------|---|
| LAPatinib  | 1000-1250 mg PO daily | To be given on an empty stomach, 1hr before or 2hr after meals. |
| <b>To be given continuously until disease progression or intolerable toxicity.</b> |                       |   |

**Special instructions:** If a dose is missed, resume with the next scheduled daily dose; don't double the dose the next day.

Avoid concomitant use with CYP3A4 inhibitors, CYP3A4 inducers, carbamazepine, voriconazole, Dexamethasone, Grapefruit, or clarithromycin.

**Treatment Description:**

| Cycle | Date | LAPatinib | Physician | Consultant |
|-------|------|-----------|-----------|------------|
| C# __ |      |           |           |            |
| C# __ |      |           |           |            |
| C# __ |      |           |           |            |
| C# __ |      |           |           |            |
| C# __ |      |           |           |            |
| C# __ |      |           |           |            |
| C# __ |      |           |           |            |
| C# __ |      |           |           |            |

**Important Notes:**

Reported grade 3/4 toxicities:  None  Hematological  Non-Hematological

If yes; Did it indicate hospitalization?  Yes  No

Did it indicate chemo-delay for ≥ 7 days?  Yes  No

Did it indicate dose reduction?  Yes  No

Did it indicate G-CSF support?  Yes  No